Research Article

High-Mobility Group Box-1 and Endothelial Cell Angiogenic Markers in the Vitreous from Patients with Proliferative Diabetic Retinopathy

Ahmed M. Abu El-Asrar, 1, 2 Mohd Imtiaz Nawaz, 1 Dustan Kangave, 1 Marwan Abouammoh, 1 and Ghulam Mohammad 1

1 Department of Ophthalmology, College of Medicine, King Saud University, Riyadh 11411, Saudi Arabia
2 Department of Ophthalmology, King Abdulaziz University Hospital, Old Airport Road, P.O. Box 245, Riyadh 11411, Saudi Arabia

Correspondence should be addressed to Ahmed M. Abu El-Asrar, abuelasrar@yahoo.com

Received 28 May 2012; Accepted 18 September 2012

1. Introduction

Ischemia-induced angiogenesis and expansion of extracellular matrix in association with the outgrowth of fibrovascular membranes at the vitreoretinal interface is the pathological hallmark in proliferative diabetic retinopathy (PDR). Vascular endothelial growth factor (VEGF), an endothelial cell mitogen that also enhances vascular permeability, is thought to be the major angiogenesis factor in PDR [1]. In addition, strong evidence indicates that chronic low-grade inflammation is implicated in the pathogenesis of diabetic retinopathy [2–3]. Sustained proinflammatory responses in diabetic retinopathy are often associated with angiogenesis [2–5]. The causal relationship between inflammation and angiogenesis is now widely accepted [6]. An emerging issue in diabetic retinopathy research is the focus on the mechanistic link between chronic, low-grade inflammation and angiogenesis.

High-mobility group box-1 protein (HMGB1) was initially discovered as a nuclear chromatin-binding protein that stabilizes nucleosome formation and facilitates transcription. Necrotic cell death can result in passive leakage of HMGB1 as the protein is then no longer bound to DNA. In addition, HMGB1 can be actively secreted by different cell types, including activated monocytes and macrophages, mature dendritic cells, natural killer cells, and endothelial cells. Extracellular HMGB1 functions as a proinflammatory cytokine [6–10] and exhibits angiogenic effects [10–14]. HMGB1 signals through the receptor for advanced glycation end products (RAGE) leading to activation of the transcription factor nuclear factor kappa B (NF-κB) and induces the expression of various leukocyte adhesion
molecules and proinflammatory cytokines, chemokines, and angiogenic factors [6–9]. These findings suggest that HMGB1 might provide the mechanistic link between chronic low-grade inflammation and angiogenesis. In a previous report, we demonstrated that HMGB1 and RAGE were expressed by vascular endothelial cells and stromal cells in PDR fibrovascular epiretinal membranes and that there were significant correlations between the level of vascularization in PDR epiretinal membranes and the expression of HMGB1 and RAGE [15]. In addition, we demonstrated increased levels of HMGB1 in the vitreous samples from patients with PDR and that HMGB1 expression was upregulated in the retinas of diabetic mice. Moreover, there were significant correlations between the vitreous levels of HMGB1 and the levels of the inflammatory biomarkers monocyte chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1) [16].

Over the years, great effort has been made to find specific markers for the angiogenic endothelial cells that can be exploited by vascular targeting agents. Among these markers, the endothelial cell activation markers vascular-endothelial-(VE-) cadherin and endoglin (Eng) stand out as reliable biomarkers of angiogenesis activity. VE-cadherin is a cell adhesion molecule localized at the endothelial junction. VE-cadherin plays a key role in angiogenesis, signaling, endothelial cell survival, and endothelial cell barrier function. The regulation of its biological activity may be the central mechanism in normal or pathological angiogenesis [17, 18]. This molecule can be shed from the cell surface and elevated serum levels of soluble VE-cadherin (sVE-cadherin) seem to be a reliable marker of endothelial angiogenic activity and/or injury [19–25].

Endoglin (Eng) (also known as CD105), a type I transmembrane glycoprotein highly expressed on proliferating vascular endothelial cells, has been identified as an accessory receptor for transforming growth factor-β (TGF-β) and is essential for angiogenesis. Eng is expressed at low to nondetectable levels in resting endothelial cells within normal tissues, but its expression strongly increases in vascular endothelial cells in sites of active angiogenesis during embryogenesis, in inflamed tissues, in healing wounds, and in tumor vessels. Therefore, Eng detection is used as a marker to analyze angiogenesis and microvascular density in tumors and has been found to be an independent prognostic indicator. Expression of Eng can be induced by hypoxia and is also upregulated in ischemic tissues [26, 27]. Furthermore, a soluble form of Eng (sEng) has been observed in the serum of patients with different types of solid malignancies [28] and of pregnant women suffering from preeclampsia [29]. Circulating levels of sEng were found to be a reliable biomarker that correlates with disease severity and has prognostic significance [28, 29]. This soluble form, which results from partial shedding of the membrane-bound form of Eng by the matrix metalloproteinase-14 (MT1-MMP) [30], has been proposed to act as a scavenger or trap for circulating TGF-β family ligands such as bone morphogenetic proteins 9 and 10, thus impairing binding to their physiological receptors indicating an important role of sEng in the regulation of angiogenesis [31].

The aim of this study was to measure the levels of HMGB1 in the vitreous fluid from patients with PDR and to correlate its levels with clinical disease activity and vitreous levels of VEGF, the angiogenic cytokine granulocyte-colony stimulating factor (G-CSF) [32–34] and the endothelial cell angiogenic markers sVE-cadherin and sEng.

2. Materials and Methods

2.1. Vitreous Samples. Undiluted vitreous fluid samples (0.3–0.6 mL) were obtained from 36 patients with PDR and 21 patients with rhegmatogenous retinal detachment (RD) without proliferative vitreoretinopathy during pars plana vitrectomy. The indications for vitrectomy in patients with PDR were traction retinal detachment and/or nonclearing vitreous hemorrhage. In patients with PDR, the severity of retinal neovascular activity was graded clinically at the time of vitrectomy using previously published criteria [35]. Neovascularization was considered active if there were visible perfused new vessels on the retina or optic disc present within tractional epiretinal membranes. Neovascularization was considered inactive (involved) if only nonvascularized, white fibrotic epiretinal membranes were present. Active PDR was present in 19 patients and inactive PDR was present in 17 patients. Vitreous samples were collected undiluted by manual suction into a syringe through the aspiration line of vitrectomy, before opening the infusion line. The samples were centrifuged (500 rpm for 10 min, 4°C) and the supernatants were aliquoted and frozen at −80°C until assay. The study was conducted according to the tenets of the Declaration of Helsinki, and informed consent was obtained from all patients. The study was approved by the Research Centre, College of Medicine, King Saud University.

2.2. Enzyme-Linked Immunosorbent Assay Kits. Enzyme-linked immunosorbent assay (ELISA) kits for human VE-cadherin (Human VE-cadherin, Cat No: DCADV0), human VEGF (Human vascular endothelial growth factor, Cat No: SVE00), human Eng (Human Endoglin/CD105, Cat No: DNDDG00) and human G-CSF (Human granulocyte-colony stimulating factor, Cat No: DCS50), were purchased from R&D Systems, Minneapolis, MN, USA. The ELISA kit for HMGB1 (human high-mobility group box-1, Cat No: STS1011) was purchased from IBL International GMBH, Hamburg, Germany.

The minimum detection limit of each ELISA kit for VE-Cadherin, VEGF, Eng, G-CSF, and HMGB1 is 113, 9, 7, 20, and 100 picograms/mL (pg/mL), respectively. The ELISA plate readings were done using FLUOstar Omega-Microplate reader from BMG Labtech, Offenburg, Germany.

2.3. Measurement of VE-Cadherin, VEGF, Eng, G-CSF, and HMGB1. The quantification of human VE-cadherin, VEGF, Eng, G-CSF, and HMGB1 in the vitreous fluid was determined using ELISA kits according to the manufacturer's instruction. For each ELISA kit, the undiluted standard served as the highest concentration and calibrator diluents served as the blank. Depending upon the detection range for
2.4. Statistical Methods. Because of the large variances that we had in our data, we used the non-parametric Mann-Whitney test to compare means from two independent groups, and the nonparametric Kruskal-Wallis test was used for conducting Analysis of Variance (ANOVA) to compare means from more than two independent groups. Correlation between continuous variables was investigated by computation of the Pearson correlation coefficient. A $P$ value less than 0.05 indicated statistical significance. Post-ANOVA pairwise comparisons of means were conducted using the Kruskal-Wallis test. For three groups, the critical $Z$-value for determining statistical significance was $Z = 2.39$. Exploratory logistic regression analysis involving forcing entry, into a logistic model, the variables of interest, was conducted to discover whether active PDR was associated with high or low levels for the variables that were investigated. The mean level of each variable was used as the cut-off value for high versus low levels. SPSS version 15 and programs LR and 3S from Bio-Medical Data Processing Version 2007 (BMDP 2007) Statistical Software (Cork Technology Pack, Model Farm Road, Cord, Ireland) were used for the statistical analyses.

3. Results

3.1. Levels of Angiogenesis Biomarkers in Vitreous Samples. HMGB1, sVE-cadherin, and sEng were detected in all vitreous samples from patients with PDR and non-diabetic patients. VEGF was detected in 36 (90%) vitreous samples from patients with PDR and in 10 (45%) vitreous samples from non-diabetic patients. G-CSF was detected in only 3 (7.5%) vitreous samples from patients with PDR and in 6 (27%) vitreous samples from non-diabetic patients.

The mean levels of HMGB1, VEGF, sVE-cadherin, and sEng in vitreous samples from PDR patients were significantly higher than those in non-diabetic patients ($P = 0.008$; $P < 0.001$; $P < 0.001$; $P = 0.003$, resp.; Mann-Whitney test) (Table 1).

3.2. Relationship between Angiogenesis Biomarkers and Activity of PDR. Comparison of mean levels of angiogenesis biomarkers among active PDR patients, inactive PDR patients, and non-diabetic patients was conducted using the Kruskal-Wallis test and the results are shown in Table 2. Mean levels differed significantly between the 3 groups from HMGB1 ($P = 0.028$), VEGF ($P < 0.001$), sVE-cadherin ($P < 0.001$), and sEng ($P = 0.006$). Post-ANOVA pairwise comparisons of means indicated that mean HMGB1 level was significantly higher in patients with active PDR than in non-diabetic patients ($Z = 2.53$). For VEGF, the mean levels were significantly higher in patients with active PDR than that in inactive PDR patients and non-diabetic patients ($Z = 3.88$; $Z = 5.46$, resp.). For sVE-cadherin, the mean levels were significantly higher in patients with active PDR and patients with inactive PDR than those in non-diabetic patients ($Z = 4.72$; $Z = 4.42$, resp.). For sEng, the mean level in patients with inactive PDR was significantly higher than that in non-diabetic patients ($Z = 3.16$).

3.3. Correlations. In the whole study group, there was a significant positive correlation between vitreous fluid levels of HMGB1 and sVE-cadherin ($r = 0.378$, $P = 0.007$). In PDR patients, there was a significant negative correlation between vitreous fluid levels of sVE-cadherin and sEng ($r = -0.517$, $P = 0.005$).

3.4. Logistic Regression Analysis. We conducted exploratory logistic regression analysis to investigate further the association between the angiogenesis biomarkers and active PDR. Active PDR was significantly associated with high levels of VEGF (odds ratio = 76.4; 95% confidence interval = 6.322–923) and high levels of sEng (odds ratio = 6.01; 95% confidence interval = 1.25–29.0).

4. Discussion

In the present study, the levels of HMGB1, VEGF, sVE-cadherin, and sEng were significantly higher in the vitreous fluid from PDR patients compared with non-diabetic patients. In contrast, G-CSF was detected in only few samples consistent with a previous study [36]. There was a significant positive correlation between the vitreous levels of HMGB1 and sVE-cadherin in the whole patient group and a significant negative correlation between sVE-cadherin and sEng in patients with PDR. Among the angiogenic factors that we investigated, VEGF and sEng had a stronger influence on the activity of PDR than the other factors.

In the present study, HMGB1 levels were significantly elevated in the vitreous fluid from patients with PDR. Furthermore, the levels were higher in patients with active PDR compared with patients with quiescent PDR. In a previous study, we demonstrated that HMGB1 expression...
was upregulated in the retinas of diabetic mice [16]. Similarly, increased vascular [37] and renal [38] HMGB1 expression was recently demonstrated in diabetic animals. In addition, hyperglycemia-induced reactive oxygen species production increased the expression of HMGB1 and RAGE in endothelial cells [39]. In patients with type 1 diabetes, serum HMGB1 levels were positively associated with markers of low-grade inflammation and endothelial dysfunction. In addition, higher serum HMGB1 levels were associated with greater prevalence and severity of albuminuria [40]. Activation of HMGB1/RAGE signaling axis is important in diabetes-induced retinal vascular inflammation. In endothelial cells, HMGB1 induces the expression of RAGE and adhesion molecules, such as ICAM-1, vascular cells adhesion molecule-1, and E-selectin, to release tumor necrosis factor-α (TNF-α), G-CSF, interleukin-8, and MCP-1 and to increase neutrophil adhesion. This proinflammatory phenotype was mediated by the activation of NF-κB and was RAGE dependent as it was inhibited by antibodies directed toward RAGE [7–10]. In our laboratory, we recently demonstrated that intravitreal administration of HMGB1 to normal rats induced significant upregulation of ICAM-1, HMGB1, and RAGE and NF-κB activation in the retina (Mohammad et al., unpublished data). In turn endothelial cells secrete HMGB1 in response to TNF-α treatment [41], suggesting a role for HMGB1 in positive feedback loop promoting inflammation. Recently, HMGB1 has been recognized as an angiogenic cytokine [10–14]. HMGB1 treatment of endothelial cells induced a proangiogenic gene expression program evidenced by the induction of VEGF and its receptors, platelet-derived growth factor receptors, integrins and matrix metalloproteinases [10]. In addition, HMGB1 induced endothelial cell migration, and sprouting [10]. HMGB1 was also identified as a specific marker of tumor endothelium [14] and as a tumor angiogenesis marker [10]. Moreover, anti-HMGB1 antibodies inhibited tumor angiogenesis [10]. Another interesting role of HMGB1 in neovascularization is its ability to attract endothelial progenitor cells to sites of tissue injury and tumors to improve neovascularization in a RAGE-dependent manner [13].

Several studies demonstrated that sVE-cadherin serum levels may reflect the intensity of angiogenesis. sVE-cadherin serum level was increased in untreated multiple myeloma patients and decreased after chemotherapy in patients in remission [19]. Similarly, circulating sVE-cadherin levels were increased in pregnant women (a physiological condition associated with increased angiogenesis) and cancer patients and were particularly increased in patients affected by hematological malignancies and decreased to normal values in patients achieving complete remission [20]. Reverse transcriptase-polymerase chain reaction was used to profile gene expression of proteins closely associated with angiogenesis. Results showed 10-fold increase in VE-cadherin during angiogenesis [25]. These findings are in agreement with another study that demonstrated that VE-cadherin was a selective marker for assessing microvessel density in breast cancer [42]. Serum sVE-cadherin levels were also increased in other pathologic states associated with endothelial dysfunction such as Behc¸et’s disease [23], rheumatoid arthritis [21], coronary atherosclerosis [22], and ovarian hyperstimulation syndrome [24]. In vitro studies demonstrated that treatment of endothelial cells with TNF-α [21], VEGF [43], matrix metalloproteinase-9 [44], and the diabetic metabolite advanced glycation end products [44] resulted in shedding of the VE-cadherin extracellular domain and loss of cell-cell contact which may lead to increased vascular permeability. The present study is the first report documenting increased levels of sVE-cadherin in the vitreous fluid from patients with PDR. In addition, our analysis showed a significant positive correlation between

Table 1: Comparisons of mean angiogenesis biomarker levels in proliferative diabetic retinopathy (PDR) and rhegmatogenous retinal detachment (RD) patients.

| Disease group | HMGB1 (ng/mL) | VEGF (ng/mL) | sVE-cadherin (ng/mL) | sEng (ng/mL) |
|---------------|---------------|--------------|---------------------|-------------|
| PDR (n = 36)  | 5.69 ± 8.5    | 0.85 ± 1.2   | 77.3 ± 63.5         | 3.64 ± 1.8  |
| RD (n = 14)   | 1.70 ± 2.1    | 0.04 ± 0.1   | 10.7 ± 9.6          | 2.22 ± 0.7  |
| P value       | 0.008*        | <0.001*      | <0.001*             | <0.003*     |

*Statistically significant at 5% level of significance.

HMGB1: high-mobility group box-1; VEGF: vascular endothelial growth factor; sVE-cadherin: soluble vascular endothelial-cadherin; sEng: soluble endoglin.

Table 2: Comparisons of mean angiogenesis biomarker levels in proliferative diabetic retinopathy (PDR) patients with or without active neovascularization.

| Disease group | HMGB1 (ng/mL) | VEGF (ng/mL) | sVE-cadherin (ng/mL) | sEng (ng/mL) |
|---------------|---------------|--------------|---------------------|-------------|
| Active PDR (n = 19) | 7.28 ± 11.1  | 1.67 ± 1.4   | 75.8 ± 53.4         | 3.28 ± 1.9  |
| Inactive PDR (n = 17) | 4.02 ± 4.1   | 0.18 ± 0.4   | 78.8 ± 74.9         | 4.04 ± 1.6  |
| RD (n = 21)    | 1.70 ± 2.1   | 0.04 ± 0.1   | 10.7 ± 9.6          | 2.22 ± 0.7  |
| P value        | 0.028*       | <0.001*      | <0.001*             | 0.006*      |

*Statistically significant at 5% level of significance.

HMGB1: high-mobility group box-1; VEGF: vascular endothelial growth factor; sVE-cadherin: soluble vascular endothelial-cadherin; sEng: soluble endoglin; RD: rhegmatogenous retinal detachment.
the vitreous levels of HMGB1 and sVE-cadherin. It is well established that endothelial dysfunction is a key feature of diabetic retinopathy [44]. On the basis of our findings, we propose that elevated levels of sVE-cadherin in the vitreous fluid from patients with PDR could be a reflection of endothelial cell activation or injury associated with angiogenesis, inflammation, and breakdown of the inner blood-retinal barrier.

The current study is the first to demonstrate that sEng is significantly upregulated in the vitreous fluid from patients with PDR. Our results are consistent with a previous report showing that plasma sEng concentration could serve as an indicator of diabetes-associated vascular pathologies such as retinopathy, hypertension, endothelial dysfunction, and cardiovascular risk [45]. Similarly, another study demonstrated that sEng could be a marker to predict cardiovascular events in patients with chronic coronary artery disease [46]. In addition, Li et al. [28] showed that plasma sEng is a valuable surrogate angiogenic marker for identifying breast cancer patients who are at high risk of developing metastasis. In a previous study, we demonstrated that Eng was expressed by vascular endothelial cells in PDR fibrovascular epiretinal membranes [47]. Therefore, it is possible that the increase in sEng in the vitreous fluid from patients with PDR resulted from Eng proteolytic shedding of the membrane-bound form associated with angiogenesis. A previous study showed elevated levels of matrix metalloproteinase-14 in the retinas of diabetic animals [48]. Matrix metalloproteinase-14 was shown in a previous report to induce shedding of the membrane-bound form of Eng [30]. Among the studied biomarkers of angiogenesis, exploratory logistic regression analysis revealed that higher levels of VEGF and sEng were associated with active PDR. These findings suggest that sEng may also represent a surrogate marker of angiogenic activity in PDR.

Endothelial dysfunction is a major characteristic of patients with diabetic retinopathy [44]. Several studies demonstrated that sEng plays an important role in endothelial cell function and in regulating angiogenesis. Forced expression of sEng increased vascular permeability. In vitro studies on endothelial cell lines showed that sEng interferes with TGF-β signaling and endothelial nitric oxide activation and thereby causes endothelial dysfunction. sEng also seems to be a regulator of vascular tone, as administration of sEng to mice induces an increase in arterial pressure by increasing vascular resistance [49]. Recently, Walseh et al. [50] demonstrated that sEng increased vascular and neural cell apoptosis in the retina, which was associated with decreased retinal function and breakdown of the blood-retinal barrier. In addition, in vitro and in vivo studies demonstrated that sEng is capable of inhibiting angiogenesis [30, 31, 49]. Our analysis demonstrated a significant negative correlation between sEng levels and the levels of sVE-cadherin in the vitreous from patients with PDR. These findings suggest a lower angiogenic activity in patients with higher levels of sEng and that the upregulation of sEng in the vitreous fluid from patients with PDR may be a protective angiogenesis eye response to suppress progression of PDR.

In conclusion, these data suggest that, along with HMGB1 and VEGF, sVE-cadherin and sEng might play a role in the pathophysiology of PDR. In addition, sVE-cadherin and sEng might be valuable angiogenic markers for PDR.

Conflict of Interests

The authors declare that they have no conflict of interest.

Acknowledgments

The authors thank Ms. Connie B. Unisa-Marfil for secretarial work. This work was supported by Dr. Nasser Al-Rasheed, Research Chair in Ophthalmology, (Abu El-Asrar A. M.).

References

[1] J. Spranger and A. E. H. Pfeiffer, “New concepts in pathogenesis and treatment of diabetic retinopathy,” Experimental and Clinical Endocrinology and Diabetes, vol. 109, no. 2, pp. S438–S450, 2001.
[2] A. M. Joussen, V. Poulaki, M. L. Le et al., “A central role for inflammation in the pathogenesis of diabetic retinopathy,” FASEB Journal, vol. 18, no. 12, pp. 1450–1452, 2004.
[3] K. Miyamoto, S. Khosrof, S. E. Bursell et al., “Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 19, pp. 10836–10841, 1999.
[4] A. M. Abu El-Asrar, S. Struyf, D. Kangave, K. Geboes, and J. Van Damme, “Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy,” European Cytokine Network, vol. 17, no. 3, pp. 155–165, 2006.
[5] A. M. Abu El-Asrar, L. Missotten, and K. Geboes, “Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes,” British Journal of Ophthalmology, vol. 92, no. 11, pp. 1534–1539, 2008.
[6] J. R. van Beijnum, W. A. Buurman, and A. W. Griffioen, “Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1),” Angiogenesis, vol. 11, no. 1, pp. 91–99, 2008.
[7] C. J. Treutiger, G. E. Mullins, A. S. M. J ohansson et al., “High mobility group 1 B-box mediates activation of human endothelium,” Journal of Internal Medicine, vol. 254, no. 4, pp. 375–385, 2003.
[8] C. Fiuza, M. Bustin, S. Talwar et al., “Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells,” Blood, vol. 101, no. 7, pp. 2652–2660, 2003.
[9] Z. G. Luan, H. Zhang, P. T. Yang, X. C. Ma, C. Zhang, and R. X. Guo, “HMGB1 activates nuclear factor-κB signaling by RAGE and increases the production of TNF-α in human umbilical vein endothelial cells,” Immunobiology, vol. 215, no. 12, pp. 956–962, 2010.
[10] J. R. van Beijnum, P. Nowak-Sliwinska, E. van den Boezem, P. hautvast, W. A. Buurman, and A. W. Griffioen, “Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1,” Oncogene. In press.
[11] S. Mitola, M. Belleri, C. Urbini et al., “Cutting edge: Extracellular high mobility group box-1 protein is a proangiogenic
cytokine,” *Journal of Immunology*, vol. 176, no. 1, pp. 12–15, 2006.

[12] C. Schlueter, H. Weber, B. Meyer et al., “Angiogenic signaling through hypoxia HMGB1: an angiogenic switch molecule,” *American Journal of Pathology*, vol. 166, no. 4, pp. 1259–1263, 2005.

[13] E. Chavakis, A. Hain, M. Vinci et al., “High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells,” *Circulation Research*, vol. 100, no. 2, pp. 204–212, 2007.

[14] J. R. Van Beijnum, R. P. Dings, E. Van Der Linden et al., “Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature,” *Blood*, vol. 108, no. 7, pp. 2339–2348, 2006.

[15] A. M. A. El-Asrar, L. Missotten, and K. Geboes, “Expression of high-mobility group box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes,” *Molecular Vision*, vol. 17, pp. 508–518, 2011.

[16] A. M. A. El-Asrar, M. I. Nawaz, D. Kangave et al., “High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy,” *Molecular Vision*, vol. 17, pp. 1829–1838, 2011.

[17] D. Vestweber, “VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 28, no. 2, pp. 223–232, 2008.

[18] E. S. Harris and W. J. Nelson, “VE-cadherin: at the front, center, and sides of endothelial cell organization and function,” *Current Opinion in Cell Biology*, vol. 22, no. 5, pp. 651–658, 2010.

[19] T. Wrobel, G. Mazur, D. Wołowiec, B. Jazwiec, E. Sowinska, and K. Kulczewski, “sVE-cadherin and sCD146 serum levels in patients with multiple myeloma,” *Clinical and Laboratory Haematology*, vol. 28, no. 1, pp. 36–39, 2006.

[20] C. Rabascio, E. Muratori, P. Mancuso et al., “Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells,” *Cancer Research*, vol. 64, no. 12, pp. 4373–4377, 2004.

[21] A. Siddib, T. Mannic, M. Arbolea et al., “Soluble VE-cadherin in rheumatoid arthritis patients correlates with disease activity: evidence for tumor necrosis factor α-induced VE-cadherin cleavage,” *Arthritis and Rheumatism*, vol. 64, no. 1, pp. 77–87, 2012.

[22] T. Soeki, Y. Tamura, H. Shinohara, K. Sakabe, Y. Onose, and N. Fukuda, “Elevated concentration of soluble vascular endothelial cadherin is associated with coronary atherosclerosis,” *Circulation Journal*, vol. 68, no. 1, pp. 1–5, 2004.

[23] Z. Habibagahi, M. Habibagahi, and M. Heidari, “Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçet’s disease,” *Modern Rheumatology*, vol. 20, no. 2, pp. 154–159, 2010.

[24] A. Villasante, A. Pacheco, E. Pau, A. Ruiz, A. Pellicer, and J. A. Garcia-Velasco, “Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome,” *Human Reproduction*, vol. 23, no. 3, pp. 662–667, 2008.

[25] S. C. Shih, G. S. Robinson, C. A. Petruzzii et al., “Molecular profiling of angiogenesis markers,” *American Journal of Pathology*, vol. 161, no. 1, pp. 35–41, 2002.

[26] P. Ten Dijke, M. J. Goumans, and E. Pardali, “Endoglin in angiogenesis and vascular diseases,” *Angiogenesis*, vol. 11, no. 1, pp. 79–89, 2008.

[27] S. E. Duff, C. Li, J. M. Garland, and S. Kumar, “CD105 is important for angiogenesis: evidence and potential applications,” *FASEB Journal*, vol. 17, no. 9, pp. 984–992, 2003.

[28] C. Li, B. Guo, P. B. Wilson et al., “Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer,” *International Journal of Cancer*, vol. 86, no. 3, pp. 122–126, 2000.

[29] H. Masuyama, H. Nakatsukasa, N. Takamoto, and Y. Hiramatsu, “Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipokines in preeclampsia,” *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 7, pp. 2672–2679, 2007.

[30] L. J. A. C. Hawinkels, P. Kuiper, E. Wiercinska et al., “Matrix metalloproteinase-14 (MMP-14)-mediated endoglin shedding inhibits tumor angiogenesis,” *Cancer Research*, vol. 70, no. 10, pp. 4141–4150, 2010.

[31] R. Castonguay, E. D. Werner, R. G. Matthews et al., “Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth,” *Journal of Biological Chemistry*, vol. 286, no. 34, pp. 30034–30046, 2011.

[32] S. T. Lee, K. Chu, K. H. Jung et al., “Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia,” *Brain Research*, vol. 1058, no. 1-2, pp. 120–128, 2005.

[33] Y. Ohki, B. Heissig, Y. Sato et al., “Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils,” *FASEB Journal*, vol. 19, no. 14, pp. 2005–2007, 2005.

[34] T. Natori, M. Sata, M. Washida, Y. Hirata, R. Nagai, and M. Makuuchi, “G-CSF stimulates angiogenesis and promotes tumor growth: Potential contribution of bone marrow-derived endothelial progenitor cells,” *Biochemical and Biophysical Research Communications*, vol. 297, no. 4, pp. 1058–1061, 2002.

[35] L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” *New England Journal of Medicine*, vol. 331, no. 22, pp. 1480–1487, 1994.

[36] S. Banerjee, V. Savant, R. A. H. Scott, S. J. Curnow, G. R. Wallace, and P. L. Murray, “Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders,” *Investigative Ophthalmology and Visual Science*, vol. 48, no. 5, pp. 2203–2207, 2007.

[37] A. Soro-Paavonen, A. M. D. Watson, J. Li et al., “Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes,” *Diabetes*, vol. 57, no. 9, pp. 2461–2469, 2008.

[38] F. Li, N. Yang, L. Zhang et al., “Increased expression of toll-like receptor 2 in rat diabetic nephropathy,” *American Journal of Nephrology*, vol. 32, no. 2, pp. 179–186, 2010.

[39] D. Yao and M. Brownlee, “Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands,” *Diabetes*, vol. 59, no. 1, pp. 249–255, 2010.

[40] J. W. M. Nin, I. Ferreira, C. G. Schalkwijk et al., “Serum high-mobility group box-1 levels are positively associated with micro- and macroalbuminuria but not with cardiovascular disease in type 1 diabetes: The EURODIAB prospective complications study,” *European Journal of Endocrinology*, vol. 166, no. 2, pp. 325–332, 2012.
[41] G. E. Mullins, J. Sunden-Cullberg, A. S. Johansson et al., "Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1," Scandinavian Journal of Immunology, vol. 60, no. 6, pp. 566–573, 2004.

[42] T. A. Martin, G. Watkins, J. Lane, and W. G. Jiang, "Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin," Histopathology, vol. 46, no. 4, pp. 422–430, 2005.

[43] A. Villasante, A. Pacheco, A. Ruiz, A. Pellicer, and J. A. Garcia-Velasco, "Vascular endothelial cadherin regulates vascular permeability: Implications for ovarian hyperstimulation syndrome," Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 1, pp. 314–321, 2007.

[44] D. Navaratna, P. G. McGuire, G. Menicucci, and A. Das, "Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes," Diabetes, vol. 56, no. 9, pp. 2380–2387, 2007.

[45] A. M. Blázquez-Medela, L. García-Ortiz, M. A. Gómez-Marcos et al., "Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients," BMC Medicine, vol. 8, article 86, 2010.

[46] T. Ikemoto, Y. Hojo, H. Kondo et al., "Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases," Heart and Vessels, vol. 27, no. 4, pp. 344–351, 2011.

[47] A. M. Abu El-Asrar, P. E. Van den Steen, S. A. Al-Amro, L. Missotten, G. Opdenakker, and K. Geboes, "Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders," International Ophthalmology, vol. 27, no. 1, pp. 11–22, 2007.

[48] S. J. Giebel, G. Menicucci, P. G. McGuire, and A. Das, "Matrix metalloproteinases in early diabetic retinopathy and their role in alternation of the blood-retinal barrier," Laboratory Investigation, vol. 85, no. 5, pp. 597–607, 2005.

[49] S. Venkatesha, M. Toporsian, C. Lam et al., "Soluble endoglin contributes to the pathogenesis of preeclampsia," Nature Medicine, vol. 12, no. 6, pp. 642–649, 2006.

[50] T. E. Walshe, M. Saint-Geniez, A. S. R. Maharaj, E. Sekiyama, A. E. Maldonado, and P. A. D’Amore, "TGF-β is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature," PLoS One, vol. 4, no. 4, Article ID e5149, 2009.